Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. The company is pioneering a transformational approach to treating cancer by harnessing the human immune system to recognize and attack cancer cells, with a TIL platform showing promising clinical data across multiple solid tumors.